Newsfiscal.ai
Leerink Partners Initiates Coverage on Kazia Therapeutics With Outperform, $30 Price Target
· Published
Article summary
Leerink Partners has initiated research coverage on Kazia Therapeutics with an 'Outperform' rating and a price target of $30 per share.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…